Brigadier Commences Preparations for Inaugural Exploration Program at Gold-Silver Picachos Property Sinaloa Mexico, Including First Ever Diamond Drilling Program Focused at Past Producing San Agustin High Grade Gold Mine
Vancouver, British Columbia–(Newsfile Corp. – August 13, 2020) – Brigadier Gold Limited (TSXV: BRG) (FSE: B7LM) (the “Company” or “Brigadier“) is pleased to announce preparations are underway for the first ever diamond drill campaign at the Company’s recently acquired 3,954 hectare Picachos Gold-Silver Property (“Picachos“), centered over the historic “Viva Zapata” National Mineral Reserve, Sinaloa, Mexico. Drilling is expected to commence in September and is planned for a minimum 5000 metres (m) in approximately 40 holes targeting four high-grade gold-silver veins.
- San Agustin mine: underground channel sampling by prior operator returned average grade of 81.22 grams per ton (g/t) gold (Au) and 73.36 g/t silver (Ag) across 1.2 m (Thunderbird Projects news release dated 18 June 1997). Values of 185 g/t Au were cut across the bottom of a production shaft (sample HBM-73175).
- Mochomos vein: historic rock chip-channel sample 26409 yielded a result of 18.5 g/t Au and 570 g/t Ag across approximately 0.5 m.
- Los Tejones vein with values of 28.6 g/t Au, and 114 g/t Ag across approximately a meter (historic rock chip-channel sample 17873).
- Fermin vein with values of 268 ppm Ag and 0.3 g/t Au across 1 m.
Ranjeet Sundher, CEO, remarks, “Brigadier’s multi-talented team has been able to identify and complete the Picachos acquisition, close $4.2 million in financings and initiate exploration on this compelling gold-silver target all within a 4-week period. We are fortunate that Brigadier’s core leadership now includes our partner Michelle Robinson who together with her team, residing in Sinaloa, are intimately familiar with Picachos, the local community, and how to shape a sustainable and beneficial presence in the region.”
The Company’s focus is proving the potential for high-grade gold-silver veins that will likely be developed using underground mining methods. The center of the 2020 exploration campaign will be the past-producing San Agustín Mine which has exploited one of the ore chutes of the major east-northeasterly trending Cocolmeca Vein System (introduced in Company press-release dated 6 July 2020). In detail, the Cocolmeca Vein system is comprised of several sub-parallel veins over a 1.5 kilometer wide zone marked in blue on the map, below. San Agustín is the best understood of these veins, mainly because it has been historically exposed underground by approximately 670 line meters of tunnels, stopes and shafts. Geologically, it appears to be disrupted by the NW trending Genardo Fault. On the northeast side of the fault, the Tejones veins might correlate to San Agustín. Collectively, this first round of drilling is designed to test approximately 1 kilometer of vein strike between the past-producing San Agustín Mine and the Tejones Prospects.
Figure 1: Map of the San Agustín Mine Area
To view an enhanced version of Figure 1, please visit:
Results on the Map are tabulated below.
Table 1. Results summary of historic rock chip-channel samples. Samples marked * have only XRF scans of homogenized pulp.
|Vein System||Historic Result||Width (m)||Sample(s)|
|Tejones||28.6 g/t Au and 114 g/t Ag||1||17873|
|Tejones||1.7 g/t Au and 16 g/t Ag||6||17874|
|Tejones||145 ppm Ag*||6||23255|
|Tejones||82 ppm Ag and 2967 ppm Pb*||4||25876|
|Tejones||2.8 g/t Au||3||27350|
|San Agustin||32.3 g/t Au and 110 g/t Ag||1.5||29883|
|San Agustin||3.4 g/t Au and 69 g/t Ag||2.5||MX259|
|San Agustin||0.3 g/t Au, 22 g/t Ag||1||MX258|
|San Agustin||0.8 g/t Au and 26 g/t Ag||2||105024 and 105025|
|San Agustin||20.1 g/t Au, 42.1 g/t Ag||1.8||MX288|
|San Agustin||184.9 g/t Au, 61 g/t Ag||1.2||HBM73175|
|San Agustin||3.2 g/t Au and 27 g/t Ag||1.5||6354-55 and 6450|
|San Agustin||121.7 g/t Au and 71 g/t Ag||1.3||29887, 14-014|
|San Agustin||25.6 g/t Au, 87 g/t Ag||0.8||105023|
|San Agustin||60.7 g/t Au and 148 g/t Ag||0.8||105021|
|San Agustin||33.4 g/t Au and 144 g/t Ag||0.8||105022|
|San Agustin||0.2 g/t Au and 67 g/t Ag||1.5||24155|
|Fermin||115 ppm Ag, 2.1% Cu, 0.8% Pb and 0.5% Zn*||2||23251|
|Fermin||0.3 g/t Au, 268 ppm Ag, 0.4% Cu, 0.6% Pb, 0.5% Zn||1||32498|
|Fermin||236 ppm Ag, 0.4% Cu, 0.2% Pb, 0.1% Zn*||3||25789|
|Fermin||194 ppm Ag, 1.6% Cu, 1.1% Pb, 0.4% Zn*||4||23497 and 25788|
|Mochomos||2.8 g/t Au and 86 g/t Ag||2.1||27352, 19066, 19067|
|Mochomos||18.5 g/t Au and 570 g/t Ag||0.5||26409|
|Mochomos||171 ppm Ag*||1||23108|
Phase 1 is anticipated to total 5170 m of PQ/HQ diamond drilling in 41 drill holes as well as approximately 3 line kilometers of trenching across several historic sample sites to systematically sample the anomalies identified by the historic work and formalize the drill targets. Most holes are planned at San Agustín and Los Tejones, with a few at Mochomos and other prospects. The drill holes will range from 90 m to 300 m in length.
Picachos is comprised of four mining concessions covering an area of 3,954 hectares and is situated in the municipality of El Rosario, in the southeastern region of Sinaloa state, Mexico. Geographically, Picachos overlaps part of the western foothills of the Sierra Madre Occidental (SMO). Picachos can be accessed from Mazatlán by state highway and paved road to the town of Cacalotán, and then by country road into the Property. Total driving distance is approximately 111 road kilometres (km) over a period of four hours. Mine workings are accessed by approximately 20 km of roads internal to the Property.
The Company has not undertaken any independent investigation of the historical information contained in this press release nor has it independently analyzed the results of the previous exploration work in order to verify the accuracy of the information. The Company believes that the historical results and other information contained in this press release are relevant to continuing exploration on the Property.
National Instrument 43-101 Disclosure
The technical content of this new release has been reviewed and approved by Ms. Michelle Robinson, MASc., P.Eng., and a Qualified Person as defined by National Instrument 43-101.
Historical underground and surface rock chip-channel samples were cut across oriented structures using a hammer and chisel. Approximately 5 kg of material was collected onto a drop-bag, then rolled and quartered. Approximately 2 kg of roughly homogenized rock chips were collected in a double-plastic bag with the numbered tag facing outwards between the bags. Sample HBM-73175 was collected from a homogenous pile of mine muck taken from the bottom of JJV Slot in the San Agustin mine at the 601 m elevation by a geologist working for Hudbay Minerals in 2013.
The samples were sent either to Acme’s preparation laboratory in Guadalajara, Jalisco, or to SGS Laboratories in Durango. At either lab, the, the samples were crushed and split. A one kg split of each sample was pulverized to -200 mesh (R200-1000) For Acme, prepared pulps were sent to the North Vancouver lab for analysis using ICP-MS methods (code 1DX), whole-rock analyses (code 4A-4B) and fire assay methods using a gravimetric finish (code Group 6Gr). For SGS, the samples were analyzed in Durango using ICP methods for base metals and silver, and fire assays with either an AA or gravimetric finish. A few rocks marked * were analyzed using a Niton portable XRF analyzer to scan homogenized sample pulp. It is the QP’s opinion that the geochemical results in Table 1are reliable prospecting information.
About Brigadier Gold Limited
Brigadier was formed to leverage the next major bull market in the natural resource sector, particularly precious metals. Our mandate is to acquire undervalued and overlooked projects with demonstrable potential for advancement.
Led by a management team with decades of experience in mineral exploration and capital markets development, we are focused on advanced exploration opportunities in politically stable jurisdictions.
For further information, please contact:
Leah Hodges, Corporate Secretary
This news release may contain statements which constitute “forward-looking information”, including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.
Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61523
ANC Cannabis Now Distributing 34 Street Cannabis Seeds from Coast to Coast
ANC Inc, Alberta’s first licensed micro cultivator, continues their national expansion with approval to supply seeds for the commercial and home grower in British Columbia, Alberta, Saskatchewan, Ontario and most recently, New Brunswick.
“Since 2017, ANC Cannabis has been forming a company built around the belief that we can create quality product that is accessible to everyone while also providing educational support and services to our consumers,” said Tairance Rutter, ANC Inc.’s VP Business Development and Marketing. Adding, “At ANC we are motivated by a passion for quality product and support for the entire growing and cultivation community. We believe that everyone, no matter their background or experience, should be able to grow their own quality cannabis plants.”
ANC is first and foremost a genetics company committed to developing the highest quality products possible. ANC is currently focused on seeds for the consumer and commercial market, with plans to release flower for retail sale in the late fall of 2020. The company has been approved for a processing licence so they can process their own product. The company has additional long-term plans to sell flower, likely in the form of pre-rolls sourced from the genetics they will be offering consumers as seed stock. This approach will allow consumers to experience the product before deciding on a cultivar. This will be part of a larger program the company calls the “Know Before You Grow” service, which will also include access to an online platform offering genetics-specific tips for home growers. ANC Inc’s VP of Research and Quality Control, Thomas Facciolo, is excited to provide answers for all our home growers’ questions.
“ANC continues to expand at a rapid pace, and we are elated to have reached the milestone of national distribution, spanning across Canada, from the West Coast in British Columbia to the East Coast in New Brunswick,” said ANC Inc President, Clayton Bordeniuk. Adding, “this is just the beginning for ANC.”
ANC has developed hundreds of different genetics that are ready for the recreational market including Fruity Hoops, Pink Lemonade, Pineapple Express, Power Kush, Triple Scoop, Bubba Kush 2.5, Chocolate Cake, Double Chocolate, 34 ST Cookies, Bubba Cheese and Sorbet 33. Each strain offers a different genetic make up, with a wide range of THC concentration, and different flowering periods, appropriate for a variety of climates for indoor and outdoor growers alike.
Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials
Vancouver, British Columbia–(Newsfile Corp. – September 29, 2020) – Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant“) or (the “Company“) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind“) has entered into a definitive agreement with Psygen Labs Inc. (“Psygen“) for the supply of psilocybin for NeonMind’s planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety. The agreement was signed on September 28th, 2020.
Figure 1: Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials
To view an enhanced version of Figure 1, please visit:
Psygen is currently acting as broker between NeonMind and a licensed dealer of restricted drugs (the “Licensed Dealer“). The Licensed Dealer holds a dealer’s licence issued under Part J of the Food and Drug Regulations (a “Dealer’s Licence“). The Supply Agreement provides that Psygen will supply the psilocybin directly once Psygen holds a Dealer’s Licence. Psygen currently has a pending application for a Dealer’s Licence.
“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”
“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem. Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”
In December 2019, NeonMind filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.
In May 2020, NeonMind completed the design of a preclinical trial to confirm that psilocybin is an effective treatment for weight loss and food cravings (the “Trial“). In July 2020, the scientific investigator chosen to lead NeonMind’s preclinical trial submitted a Section 56 Exemption application to Health Canada for the use of psilocybin in the Trial. An exemption must be granted and a final agreement entered into with the laboratory before the Trial can begin.
According to the World Health Organization, in 2016, more than 1.9 billion adults or 39% of adults, 18 years and older, were overweight. Grandview Research projects that the global weight management market is expected to grow at a compound annual growth rate of 8.3% from 2019 to 2025 to reach USD $442.3 billion by 2025.
About Psygen Labs Inc.
Psygen is a privately held company based in Calgary, Alberta. Psygen specializes in synthetic manufacture of psychedelic drug substances and drug products. Psygen provides non-exclusive access to GMP compliant psychedelic drug substances and drug products for clinical trials, therapeutic applications and pre-clinical studies. Psygen has entered into a number of definitive agreements for ongoing supply of drug substances and is positioned to be a lead supplier in the emerging commercial market for psychedelic drug substances and drug products. Psygen has sponsored a Licensed Dealer who holds a license for the manufacture, sale, import, export, and analysis of LSD, psilocybin, MDMA, DMT, 2C-B, and mescaline. Chemists working with Psygen currently operate from a manufacturing laboratory at the University of Alberta. Psygen has applied to Health Canada for a Dealer’s License that will allow Psygen to manufacture, possess, sell, import, export, research, develop, and analyze psychedelic drug substances and drug products. Psygen is currently building out a 6,000 square foot lab capable of large-scale synthesis, formulation and distribution of the above and additional psychedelics to a GMP standard. Psygen intends to be the leader in psychedelic medicine supply chain solutions and is committed to supporting the renaissance in use of psychedelics for research and clinical treatment of a wide variety of mental health issues.
About NeonMind Biosciences Inc.
NeonMind is engaged in research and development of products that use medicinal and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 69% of the issued and outstanding stock of NeonMind.
About Better Plant Sciences Inc.
Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.
Investor Relations Contact:
Penny White, President & CEO
Kevan Matheson, Investor Relations
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64798
CGOC Announces Management Changes and Director Appointment
Toronto, Ontario–(Newsfile Corp. – September 28, 2020) – Cannabis Growth Opportunity Corporation (CSE: CGOC) (“CGOC“, or the “Company“), a cannabis focused investment corporation with both public and private cannabis holdings, announced today that Paul Andersen, the Company’s Chief Financial Officer, has been appointed as the Company’s Chief Executive Officer replacing Sean Conacher, the Company’s former Chief Executive Officer. Mr. Phillip Millar has been appointed as the President and Chief Operating Officer and Michael Johnston will replace Mr. Andersen as the Chief Financial Officer and Corporate Secretary and has also been appointed as a director of the Company. Each of the foregoing changes are effective immediately.
Mr. Millar has extensive experience in the North American Cannabis market as a senior executive. His legal and military training brings a refreshing perspective to a market that values integrity, accuracy and reliability. The Company’s board of directors believes that Mr. Millar’s strategic vision and ability to synergize and coordinate multiple stakeholders towards a shared mission will add value to shareholders.
Mr. Johnston is a CPA, CA, and is currently the chief financial officer of Minsud Resources Corp., a mineral exploration company trading on the TSX Venture Exchange. From November 2015 to April 2018, he was the CFO of Canada House Wellness Group Inc., a Canadian cannabis company that currently produces medical grade cannabis and operates several clinics across Canada
CGOC is an investment corporation that offers unique global exposure to the emerging global cannabis sector. CGOC’s main objective is to provide shareholders long-term total return through its actively managed portfolio of securities, both public and private, operating in, or that derive a portion of their revenue or earnings from products or services related to the cannabis industry.
This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, involve risks and uncertainties that could cause actual results to differ materially from those contemplated in those forward-looking statements and information. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the Company’s business plan and matters relating thereto, and risks associated with the Company’s investments and financial objectives, as well as other risks and uncertainties, including but not limited to those detailed from time to time in the Company’s public filings on SEDAR. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
For further information please contact Cannabis Growth Opportunity Corporation:
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64803
Cannabis4 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis3 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis4 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis3 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis2 weeks ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)
Cannabis4 weeks ago
Fernhill Beverage Branches Out for Success!
Cannabis4 weeks ago
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru
Cannabis3 weeks ago
Monument Health Chooses Nuance Dragon Ambient eXperience to Transform Physician-Patient Encounters with Ambient Clinical Intelligence